A Phase II study of Concurrent Chemoradiation plus Durvalumab (MEDI4736) followed by Surgery followed by Adjuvant Durvalumab (MEDI4736) in medically operable patients with surgically resectable Stage III (N2) Non-Small Cell Lung Cancer: A Hoosier Cancer Research Network Clinical Trial LUN 17-321
Brief description of study
The purpose of the study is to determine the safety and efficacy of having Durvalumab with concurrent chemoradiation followed by surgery in patients with surgically resectable, medically operable stage IIIA NSCLC. We want to know if neoadjuvant Durvalumab will improve patients' responses to therapy when incorporated with chemoradiation prior to surgery.
Clinical Study Identifier: s18-01157
ClinicalTrials.gov Identifier: NCT03871153
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
